Zhihang Chen1, Marie-France Penet2, Balaji Krishnamachary1, Sangeeta R Banerjee2, Martin G Pomper2, Zaver M Bhujwalla3. 1. JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD, 21205, USA. 2. JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD, 21205, USA; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. 3. JHU ICMIC Program, Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD, 21205, USA; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. Electronic address: zaver@mri.jhu.edu.
Abstract
Metastatic prostate cancer causes significant morbidity and mortality and there is a critical unmet need for effective treatments. We have developed a theranostic nanoplex platform for combined imaging and therapy of prostate cancer. Our prostate-specific membrane antigen (PSMA) targeted nanoplex is designed to deliver plasmid DNA encoding tumor necrosis factor related apoptosis-inducing ligand (TRAIL), together with bacterial cytosine deaminase (bCD) as a prodrug enzyme. Nanoplex specificity was tested using two variants of human PC3 prostate cancer cells in culture and in tumor xenografts, one with high PSMA expression and the other with negligible expression levels. The expression of EGFP-TRAIL was demonstrated by fluorescence optical imaging and real-time PCR. Noninvasive (19)F MR spectroscopy detected the conversion of the nontoxic prodrug 5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU) by bCD. The combination strategy of TRAIL gene and 5-FC/bCD therapy showed significant inhibition of the growth of prostate cancer cells and tumors. These data demonstrate that the PSMA-specific theranostic nanoplex can deliver gene therapy and prodrug enzyme therapy concurrently for precision medicine in metastatic prostate cancer.
Metastatic prostate cancer causes significant morbidity and mortality and tn>an class="Chemical">here is a critical unmet need for effective treatments. We have developed a theranostic nanoplex platform for combined imaging and therapy of prostate cancer. Our prostate-specific membrane antigen (PSMA) targeted nanoplex is designed to deliver plasmid DNA encoding tumor necrosis factor related apoptosis-inducing ligand (TRAIL), together with bacterial cytosine deaminase (bCD) as a prodrug enzyme. Nanoplex specificity was tested using two variants of humanPC3prostate cancer cells in culture and in tumor xenografts, one with high PSMA expression and the other with negligible expression levels. The expression of EGFP-TRAIL was demonstrated by fluorescence optical imaging and real-time PCR. Noninvasive (19)F MR spectroscopy detected the conversion of the nontoxic prodrug 5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU) by bCD. The combination strategy of TRAIL gene and 5-FC/bCD therapy showed significant inhibition of the growth of prostate cancer cells and tumors. These data demonstrate that thePSMA-specific theranostic nanoplex can deliver gene therapy and prodrug enzyme therapy concurrently for precision medicine in metastatic prostate cancer.
Authors: X-W Ren; M Liang; X Meng; X Ye; H Ma; Y Zhao; J Guo; N Cai; H-Z Chen; S-L Ye; F Hu Journal: Cancer Gene Ther Date: 2006-02 Impact factor: 5.987
Authors: Mohamed E El-Zaria; Afaf R Genady; Nancy Janzen; Christina I Petlura; Denis R Beckford Vera; John F Valliant Journal: Dalton Trans Date: 2014-04-07 Impact factor: 4.390
Authors: Sangeeta Ray Banerjee; Mrudula Pullambhatla; Youngjoo Byun; Sridhar Nimmagadda; Gilbert Green; James J Fox; Andrew Horti; Ronnie C Mease; Martin G Pomper Journal: J Med Chem Date: 2010-07-22 Impact factor: 7.446
Authors: Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper Journal: J Med Chem Date: 2008-07-19 Impact factor: 7.446
Authors: Sangeeta R Banerjee; Catherine A Foss; Allen Horhota; Mrudula Pullambhatla; Kevin McDonnell; Stephen Zale; Martin G Pomper Journal: Biomacromolecules Date: 2016-12-21 Impact factor: 6.988
Authors: Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell Journal: ACS Nano Date: 2018-02-06 Impact factor: 15.881